<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803855</url>
  </required_header>
  <id_info>
    <org_study_id>D1950C00001</org_study_id>
    <secondary_id>EudraCT No.: 2008-006228-76</secondary_id>
    <nct_id>NCT00803855</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers</brief_title>
  <acronym>SAD</acronym>
  <official_title>A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 Including an Open Food Effect Panel in Healthy Male and Non-Fertile Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and tolerability of AZD1446
      following single dose administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of AZD1446 by assessment of serious adverse events, ECGs, vital signs and laboratory variables</measure>
    <time_frame>From first to last visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the single ascending dose pharmacokinetics of AZD1446</measure>
    <time_frame>PK sampling taken at defined timepoints during residential period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the single dose of AZD1446 on food interaction</measure>
    <time_frame>From first to last visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD1446 Oral or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration of AZD1446 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1446 Oral, with or without food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration of AZD1446 with or without food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1446</intervention_name>
    <description>oral, single dose</description>
    <arm_group_label>AZD1446 Oral or placebo</arm_group_label>
    <arm_group_label>AZD1446 Oral, with or without food</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  physical healthy volunteers

          -  weight between 50 to 100 kg and a body mass index (BMI) between 19 and 30 kg/m2

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder.

          -  History of severe allergy/hypersensitivity reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Meulien, MD, PhD, MSD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Södertälje</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingemar Bylesjö, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca CPU Huddinge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>May 14, 2009</last_update_submitted>
  <last_update_submitted_qc>May 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Didier Meulien, MD, PhD, Medical Science Director, Clinical Neuroscience, Therapeutic area Alzheimers Disease and Cognition</name_title>
    <organization>AstraZeneca R&amp;D Södertälje</organization>
  </responsible_party>
  <keyword>single dose</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>food interaction</keyword>
  <keyword>AZD1446</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

